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Abstract Pre-exposure prophylaxis (PrEP) has the potential to become a powerful biomedical approach to HIV
prevention; however, its success depends on behavioral and
social factors that may determine its appropriate use. This
article is designed to facilitate interdisciplinary empirical
analogies relevant to PrEP implementation, reviewing
behavioral and social science findings that may provide
lessons critical to the success of PrEP as a biomedical–
behavioral prevention strategy. As we prepare for the
dissemination of new biomedical approaches to HIV
prevention, integrating the state of the science across
disciplines may result in innovative strategies for implementation that can enhance their success.
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Introduction
Pre-exposure prophylaxis (PrEP) refers to daily or intermittent oral administration of antiretroviral drugs designed to
protect high-risk HIV-negative individuals from infection.
As a new biomedical approach to HIV prevention, PrEP has
the potential to become a powerful tool. Simulation models
indicate that an effective PrEP program could substantially
reduce the incidence of HIV transmission both internationally
and among high-risk populations in the United States [1, 2].
At present, clinical trials of PrEP are underway in 13
countries, and the US Centers for Disease Control and
Prevention has called PrEP “one of the most important new
prevention approaches being investigated today” [3].
Recent discussions of advances in biomedical prevention
emphasize the importance of community participation and
collaboration in the success of product development,
testing, and dissemination [4, 5]. This focus on collaboration and participation must apply to the scientific community as well. Too often, progress is stymied by what might
be called a “failure of analogy,” that is, a neglect of
empirical findings from other research areas or disciplines
that are relevant to emerging prevention strategies. The
success of PrEP as a biomedical prevention strategy
depends on behavioral and social factors that may determine its appropriate use. Consequently, scientific insights
from behavioral and social research are crucial to PrEP
success. This article is designed to facilitate interdisciplinary
empirical analogies relevant to PrEP implementation,
reviewing behavioral and social science findings that may
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provide lessons critical to the success of PrEP as a
biomedical–behavioral prevention strategy.
Should PrEP prove effective in clinical trials, successful
implementation will require support for three individual-level
behaviors: 1) adoption of PrEP by high-risk individuals; 2)
adherence to PrEP regimens by individuals who adopt it;
and 3) sustained risk reduction practices by these same
individuals. For each of these behaviors, we review the state
of the science from neuroeconomics, decision-sciences,
social and health psychology, health communication, and
across other public health research areas that provide the
most pertinent empirical analogies for PrEP as a prevention
strategy (Table 1). We then make specific recommendations
for the application of this evidence to PrEP-specific research
and practice.

Adoption of PrEP
The introduction of new prevention technologies can be a
challenging process, as high-risk individuals are often
reluctant to adopt prophylactic treatment [6•, 7, 8]. Similar
concerns are likely to occur with the adoption of PrEP. In
developing strategies to promote PrEP adoption,
researchers and practitioners should consider findings
from three areas of behavioral and social sciences
research: 1) information processing regarding risk and
probability; 2) framing effects; and 3) the role of stigma
in determining health behavior. Findings from each area
provide important insights into the decision making of
potential PrEP adopters and their response to potential
PrEP information campaigns.
Research on communication of risk and probability
information emerges from the disciplines of behavioral
economics and social psychology, which study the ways in
which people encode, retain, and apply probability information to make choices that involve risk/benefit calculations. In this paradigm, probability information refers to
individuals’ understanding of the likelihood of particular
outcomes—both positive and negative—associated with a
given behavior. Risk refers to individuals’ understanding of
the probability of these outcomes, plus the value they
ascribe to these outcomes. For example, decision-making
around risky sexual behavior involves both probability
information (ie, perceived likelihood of contracting HIV or
another STD by engaging in this behavior) and risk
information (ie, integration of these probabilities with both
negative value placed on HIV/STD infection and the
positive value placed on having unprotected sex). Effective
communication regarding risk and probability will be
essential to PrEP adoption because PrEP is unlikely to
provide complete protection from HIV infection [9]. Public
information and provider-based education about PrEP must
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effectively communicate information about efficacy in a
manner that allows high-risk populations to make informed
decisions about its use. In a recent meta-analytic review of
empirical findings on communication about risk and
probability, Visschers and colleagues [10••] make a series
of specific recommendations regarding the most effective
methods for presenting probability (eg, that a certain drug
might confer only 60% protection) to insure that consumers
are able to understand and apply it to their decision-making
processes. For example, increasing the personal relevance
of risk information by presenting probability estimates
tailored to an individual’s specific characteristics and
context consistently results in more accurate comprehension and application of risk information. These and other
findings from the literature on information processing [11]
will be vital to the development of both public information
campaigns and tailored personal messages to promote PrEP
acceptability and adoption.
In addition to understanding the best strategies for
presenting PrEP-related risk and probability information, it
is important to understand factors that impact potential users’
ability to comprehend this information and apply it to their
decision-making. According to the heuristic-systematic information processing model, individuals process new information either systematically—ie, by conducting a deliberative,
in-depth analysis—or heuristically—ie, by using simple
inferential rules or shortcuts [12]. When individuals process
information heuristically, they are more vulnerable to biases
that might impair their decision-making. One of the
challenges to the development of effective PrEP communication strategies will be maximizing the likelihood that
patients and consumers use more deliberate, systematic
decision-making as they consider PrEP adoption—eg,
thoughtfully considering the pros and cons of PrEP use
and the feasibility of regular self-administration of drugs in
their daily lives—rather than more spontaneous, heuristic
decision-making. Consistent with evidence from other
similar social psychological models of communication and
persuasion [13], the likelihood of systematic processing is
determined by individuals’ capacity for systematic processing (ie, cognitive capacity, attention, and time) and their
motivation to engage in this type of processing (ie, interest,
personal relevance). In constructing messages about PrEP
adoption, it will be critical to consider ways to facilitate
capacity and motivation among potential consumers. For
example, providers must insure that PrEP information is
presented to patients in a setting in which they have
sufficient time and energy to engage with the message, and
in a manner that optimizes personal relevance and motivation to attend to the message. Behavioral science also
emphasizes characteristics of the messenger or communicator that maximize decision-making within the target or
consumer [13]. Accordingly, research must examine health

Discipline

PrEP relevance

Risk
compensation

Sexual risktaking and
HAART

Munro et al. [39••], 2007: Review of over 30 behavioral change theories
applicable to long-term treatment adherence and assessment of the
evidence for their effectiveness in predicting behavior change

Stirratt and Gordon [30••], 2008: Review of three areas in which HIV treatment
adherence literature can inform research on biomedical prevention strategies
Padian et al. [32], 2008: Review of biomedical interventions to prevent
HIV and discussion of challenges and recommendations for future work

Hirsch-Moverman et al. [6•], 2008: Review of 78 studies regarding
predictors of latent tuberculosis infection medication adherence and
intervention efficacy
Rosenberg et al. [27], 1995: Review of factors that predict poor OCP
adherence and recommendations for improving OCP adherence

Mahajan et al. [17•], 2008: Review of literature on HIV/AIDS stigma in
theory, assessment, intervention, and policy analyses

Edwards et al. [16], 2001: Review of literature on manipulation of risk and
benefit information and framing effects in clinical settings

Visschers et al. [10••], 2009: Meta-analysis of 45 empirical articles about
probability in risk communication related to medical or health risk
Reyna et al. [11], 2009: Review of literature on health numeracy, detailing
mechanisms through which it impacts health outcomes, treatment
adherence, and risk perception
Sanfey and Chang [12], 2008: Review of evidence for the dissociation
between automatic and controlled processing in decision-making from
behavioral economics and neuroscience

Further reading

Lessons learned from past experience in the development of targeted
Rotheram-Borus et al. [37], 2009: Review of evidence-based interventions
prevention interventions can be adapted for the specific context of PrEP
to reduce HIV risk behavior and discussion of common factors and
recommendations
Public health;
Understanding the impact of beliefs around viral suppression on condom Crepaz et al. [40], 2004: Meta-analysis of the association between HAART
health
use and the relationship between antiretroviral adherence and sexual risk
and sexual risk behavior
psychology
can inform prevention messages targeting PrEP users, especially those in Kalichman et al. [41], 2010: Contrasts two models for understanding the
serodiscordant relationships
association between adherence and HIV transmission risk
Health psychology Provides a framework for predicting the potential impact of PrEP adoption Eaton and Kalichman [33], 2007: Review and meta-analysis of literature on
on sexual risk practices in different populations
risk compensation in response to HIV vaccines, microbicides, antiretrovirals, and circumcision

C. Sustained risk reduction
HIV prevention
Public health/HIV
interventions

A. Adoption
Risk
Decision-sciences; PrEP adoption necessitates complex communication with patients
communication
Risk analysis
regarding PrEP efficacy and its implications for relative risk reduction
Health numeracy Medical decision- Some PrEP adopters may have limited ability to understand and apply
making; health
numerical information, impacting both adoption and adherence to PrEP
communication
Heuristic vs
Neuro-economics Decision-making around PrEP adoption and sustained adherence will be
systematic
impacted by the synergistic interaction of both deliberative and
processing
associative or affective factors; adequate support of patients must
consider the influence of both types of processes
Framing effects
Health
Development of social marketing campaigns for PrEP must consider the
psychology;
influence of the framing of information about a new technology on
health
perceptions of personal risk and patient decision-making
communication
Stigma
Sociology; public HIV stigma is likely to be a significant barrier to PrEP adoption and
health
adherence
B. Adherence
Latent
Infectious disease Prophylactic treatment taken daily; potential for side effects; difficult for
tuberculosis
patients to make the connection between treatment and risk reduction
infection
Oral
Reproductive
Pills taken daily to prevent sexual risk; similar challenges regarding
contraceptive
health
sustained condom use; similar disconnect between pill-taking and the
pills (OCP)
sexual act
HIV ART
Public health/HIV Lessons learned from use of similar medications in similar populations can
inform PrEP adherence interventions
Other biomedical Public health/HIV Experience with strategies such as microbicides, male circumcision, STD
approaches to
treatment can inform PrEP adherence and risk reduction
HIV prevention
Theories of
Behavioral
Successes and failures in the application of existing behavioral theories to
health behavior
sciences
adherence interventions can inform selection of theoretical models for
PrEP intervention development

Concept/topic

Table 1 Empirical analogies to guide PrEP research and practice
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HAART highly active antiretroviral therapy; PrEP pre-exposure prophylaxis

Social psychology; PrEP represents a unique opportunity to activate an HIV prevention role- Hagger et al. [49], 2007: Examination of the role of identity in determining
sociology
identity to promote behavioral synergy; presenting PrEP adoption as part intention and behavior for three health behaviors
of a “prevention activist” identity may facilitate adherence and sustained
risk reduction

Emotional
systems in
decisionmaking
Identity

Fuzzy Trace
Theory (FTT)

PrEP relevance
Discipline
Concept/topic

Table 1 (continued)

Behavioral
Sustained risk reduction on PrEP requires ongoing risk assessment and its Reyna [43•], 2008: Review of FTT and discussion of its relevance to health
economics;
application to decision-making; FTT explains how individuals use both
and medical decision-making; presentation of theory-based intervention
decision research “gist” and “verbatim” information to inform risk perception and decision- strategies
making
Neuro-economics Managing conflicting emotions and affective cues will be critical to
Gutnik et al. [47••], 2006: Reviews evidence of emotional aspects of
sustained sexual risk reduction on PrEP
decision-making and develops a model for applying these findings to
understanding sexual risk
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Further reading
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provider characteristics—such as communication style,
clarity, and empathy—that facilitate attention and responsiveness among potential PrEP users.
The second major concept that can inform PrEP
adoption campaigns involves research on framing effects.
Framing effects are a central tenet of Prospect Theory [14],
which argues that decision-making is significantly affected
by the manner in which choices are presented. Because
PrEP may show only partial efficacy in protecting against
HIV infection, the communication and framing of the
relative merits and limitations of this strategy are crucial.
Behavioral science has shown that, when faced with an
identical decision (eg, between a pill that protects 60% of
the time versus one that fails to protect 40% of the time),
individuals react differently when the choice is framed in
terms of potential benefits (“gain” frame) compared to
potential harm (“loss” frame) [15]. Research in the
application of framing effects to decision-making regarding
prevention behavior suggests that presentation of PrEP in
either a gain frame (eg, “taking PrEP will help protect you
against HIV”) or a loss frame (eg, “if you don’t take PrEP,
you increase your risk of becoming infected with HIV”)
may have significant effects on adoption [16], but it is
currently unclear which may be more effective. More
research is needed into the application of framing effects
to the specific dynamics surrounding PrEP, but a nuanced
understanding of framing effects is critical to the presentation of PrEP information to potential consumers.
Third, efforts to maximize PrEP adoption can be
informed by research from social and health psychology
on the impact of perceived stigma on health behavior [17•].
Research suggests that individuals may act in ways that
might undermine their objective self-interests in order to
reduce their association with a stigmatized condition [18].
For example, in order to differentiate themselves from highrisk groups, some individuals might underestimate their risk
of having contracted a stigmatized illness, particularly HIV
or other sexually transmitted diseases [19]. This underestimate of risk often translates into lower rates of testing and
treatment for stigmatized conditions, and poses a significant
barrier to uptake of vaccines or other prophylaxis [20].
Issues of HIV-related stigma are particularly relevant for
PrEP adoption, as individuals may see taking PrEP as an
admission that they are engaging in behaviors that put them
at risk for infection. Normalization of testing or prophylactic treatment through opt-out policies, and carefully
delivered PrEP education counseling, may lessen the
negative impacts of stigma on potential user initiation of
PrEP [21]. The success of PrEP as a prevention strategy
will be impacted by ongoing structural and societal efforts
to reduce HIV stigma, but the role of stigma must be
considered in the development of strategies to encourage
PrEP adoption.
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Adherence to PrEP
Following adoption of PrEP, it will be critical to develop
strategies to improve and support adherence to PrEP
regimens. Nonadherence to prescribed regimens continues
to be one of the most significant challenges to successful
HIV treatment [22]. Suboptimal adherence is common
among patients prescribed prophylactic regimens, and has
been documented in other types of HIV-related prophylaxis
[23, 24]. In recent PrEP trials, adherence rates approached
only 70% [25, 26].
The most important analogies that provide lessons for
PrEP adherence can be drawn from investigations of other
types of drug treatment, including anti-malarial prophylaxis,
treatment for latent tuberculosis infection (LTBI), and daily
oral contraceptive pills (OCP), as well as the extensive
literature on adherence to HIV medications themselves.
Although the research is vast, three consistent findings
emerge across almost all adherence investigations: 1) the
importance of complete and detailed patient education at
regimen initiation; 2) the role of structural issues in
determining adherence behavior; and 3) the need for
comprehensive approaches to adherence support. Each of
these findings will be critical to the development of
supportive interventions for PrEP users.
In multiple studies across prophylactic technologies,
adherence is strongly associated with patients’ understanding of drug information [24, 27]. At the most basic level,
PrEP adherence will be dependent on clear and comprehensive messages regarding proper administration and
mechanisms of action. In a large-scale review of factors
affecting adherence to treatment for LTBI [6], perceived
severity of TB, perceived susceptibility to TB, and
perceived accuracy of LTBI diagnosis were all identified
as correlates of LTBI adherence. While perceived severity
of and susceptibility to HIV infection will be critical
determinants of PrEP adoption, these factors must also be
addressed as motivators of sustained adherence to a PrEP
regimen. For example, if high-risk individuals taking PrEP
for a relatively brief time remain HIV-negative at subsequent
testing, they might perceive themselves at low personal
susceptibility for HIV infection and, consequently, discontinue PrEP use. In the absence of continued reminders of
personal susceptibility for and severity of HIV infection,
target users may question the appropriateness of PrEP
prescription and need for adherence. Lessons from the LTBI
literature indicate that patient education regarding PrEP must
address these issues directly, ensuring that patients have an
accurate assessment of the severity of HIV infection, their
personal risk for transmission, and the potential of PrEP to
reduce this risk.
Drug-related toxicity and side effects have also been
identified as critical factors in nonadherence across medi-
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cations, including both prophylactic regimens [6•] and
treatment of chronic illnesses [28]. Research suggests two
factors are critical to patient education at drug initiation.
First, providers should distinguish between particular side
effects that a particular patient is willing to tolerate and
those that he or she is not. Research indicates that patients
often have a specific intolerable side effect that varies by
individual [29], and this information can be used to select a
particular PrEP regimen or to strategize about medication to
mitigate specific effects. Second, providers should help
patients think through specific action plans that can be
initiated in the event that intolerable side effects are
experienced, including strategizing about over-the-counter
medication that could mitigate side effects in the time it
takes to make a medical appointment, or discussing the
importance of condom use in the event that PrEP is
suspended.
A third finding relevant to patient education around
PrEP initiation is the importance of discussing when,
where, and how patients will take the new medication. In
a large retrospective study of OCP compliance in the
United States and Europe, integrating pill-taking into a
regular routine was the strongest single factor associated
with adherence [27]. Similar findings have been identified
in the adherence literature across illnesses [28]. Sustained
adherence to PrEP regimens will be possible only to the
extent that high-risk individuals are able to incorporate the
prophylactic treatment into their everyday lives. Adherence
promotion strategies may need to differentiate between
daily versus intermittent PrEP dosage regimes should both
be proven effective, as each dosage regimen may be
associated with unique adherence challenges.
In addition to these shared insights about patient
education, a second set of findings from the larger
adherence literature is the emphasis on structural—ie,
societal and social—factors that influence adherence.
Access to affordable, convenient, and culturally competent
medical care emerges consistently as one of the most
important determinants of medication adherence [30••].
Other structural issues, such as housing stability and access
to mental health services for depression or substance use,
are also critical factors that enable sustained adherence.
These structural issues are important considerations for
users in resource-deprived settings, where access to clinics
and private places to store and administer pills may be
lacking. As discussed above, stigma associated with HIV
infection may negatively impact PrEP adoption, but even
once adopted, HIV-related stigma may act as a structural
barrier to adherence. Individuals with HIV and other
stigmatized conditions report needing to hide medications
and not wanting to take pills in front of other people, as
well as difficulties managing or explaining side effects [31].
Stigma concerns will be important in deciding how broadly
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to target PrEP; if PrEP is offered only to the highest-risk
individuals, there is a potential for stigmatizing PrEP use
itself. Providing systems that support PrEP adopters in
managing societal and social factors must be considered in
the promotion of PrEP adherence on a large scale.
Finally, adherence research has seen a call for a more
integrated and comprehensive approach to intervention
development. Recent reviews of advances in HIV medication adherence strategies for HIV [22, 30••] and LTBI [6•]
emphasize the need for a multidisciplinary, multi-method,
and multi-behavioral focus in adherence intervention
development [32]. In addition, recent reviews draw attention to a mismatch between the relatively brief duration of
most behavioral interventions versus the long-term timeframe in which patients are expected to maintain target
behaviors. To provide ongoing reinforcement to PrEP users,
behavioral supports and adherence counseling could be
integrated into regular clinic visits that become standard of
care for PrEP users. Underhill and colleagues (in this issue)
argue for an expanded “implementation appropriate”
definition of PrEP as a prevention strategy, including not
only distribution of antiretroviral medications, but also
provision of ongoing HIV testing, behavioral intervention,
and integration of PrEP into an overall care platform.
Similar to OCPs, PrEP is a prevention method that is not
coitally dependent, as in the case of condom use, and has
the potential to be sustained significantly longer than other
prophylactic regimens such as LTBI or anti-malarial
treatment. In developing supportive interventions for PrEP
users over time, clinicians and researchers must consider
the unique challenges of a prevention method that must be
integrated into everyday life rather than associated with a
specific sexual act. For example, women often report
sporadic OCP use during periods of decreased sexual
activity [27]. Although trials of intermittent PrEP are
underway, little is currently known about the efficacy of
periodic or selective PrEP use, and the potential consequences
of PrEP discontinuation or “holidays,” as observed in the
HAART literature. If PrEP is proven efficacious in clinical
trial settings future research on periodic use will be essential,
as it is almost certain to occur.

Risk Reduction
The third and perhaps most important behavior related to
PrEP effectiveness is sustained sexual risk reduction among
its users. Both clinicians and researchers have expressed
concern about detrimental effects of PrEP adoption on other
sexual risk reduction practices, due in part to increased HIV
complacency and reduced perceptions of risk [33]. One
ongoing concern in PrEP discussions is the potential for
risk compensation, or an increase in HIV risk behavior
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following PrEP initiation due to the perception that one is less
susceptible to infection. Indeed, a behavioral economics
analysis has shown that, at the population level, prevalence
of sexual risk behaviors tends to increase following the
introduction of new HIV prevention technologies [34]. Costeffectiveness models conclude that the positive impact of
PrEP may be offset by even modest increases in risk
behavior [1, 2, 35]. For this reason, any positive long-term
impacts of PrEP will be dependent on the delivery of
behavioral interventions that support high-risk individuals in
combining PrEP use with sustained risk reduction practices—
including condom use, partner reduction, serostatus discussion, and repeat HIV testing.
The state of the science best applied to PrEP-focused
behavioral interventions begins with over three decades of
HIV prevention research and intervention development.
Recent reviews of efficacious HIV and STI prevention
interventions [36–38] and over 30 theories of behavior
change that have most often guided intervention development [39••] can provide an important framework within
which to develop PrEP-specific interventions and integrate
PrEP into existing prevention efforts. In addition, it is
important to consider findings regarding the association
between beliefs about reduced infectiousness and increased
risk behavior among HIV-positive individuals on HAART
[40, 41]. These findings and the dynamics they uncover
relate directly to PrEP use, both because of the number of
PrEP adopters who may be in serodiscordant relationships
with partners already taking HAART, and also because
beliefs about reduced infectiousness may lead to behavioral
disinhibition among PrEP users more broadly. In addition
to lessons from HIV itself, two areas of research across
behavioral sciences provide important empirical analogies
to guide the development of PrEP-focused risk-reduction
interventions: 1) research on dynamics of risk perception;
and 2) examinations of the role of identity in intention and
behavior.
Many theories of behavior change used to develop HIV
prevention interventions begin with the idea that individuals need accurate information in order to make choices that
will reduce health risks. However, few interventions have
integrated empirical research on dynamics of risk perception into the creation of their informational components.
Risk perception is likely to play a pivotal role in decisions
about condom use on PrEP [42]. Research on mechanisms
and processes of risk perception emerges from decision
sciences and behavioral economics, focusing on the ways in
which individuals understand both personal and societallevel risks and use this information to guide decisionmaking. According to Fuzzy Trace Theory (FTT), judgment
and decision-making rely primarily on “gist” rather than
“verbatim” representations of information [43•]. Gist
representations are qualitative (eg, that PrEP is “good”);
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they capture the gut-level meaning of information (eg, that
PrEP protects against HIV), but are impacted heavily by
emotion, past experience, culture, and level of development
(eg, that using PrEP is similar to using ART). This reliance
on gist representations is often associated with inaccurate
risk perception [43•], because it minimizes the important
nuances, probabilities, and outcomes associated with the
information. However, an overemphasis on verbatim, or
quantitative, risk perception (eg, specific effect sizes
from a PrEP trial) can also lead to inaccuracies. For
example, individuals underestimate personal risk when
they weigh the objective risks and benefits associated with a
single act of unprotected sex, rather than focusing on gist
perceptions that are linked to the cumulative risk of
repeated unprotected acts [44].
Relatedly, PrEP intervention development may benefit
from emerging research on the role of affect in risk
perception and risky decision-making. Social psychological
theories of emotion regard affect as a primary and dominant
influence on attitudes, judgments, and behavior, often
overriding or shaping cognition [45]. Other models focus
on factors that determine the relative strength of “cold”
cognitive systems and “hot” emotional systems in selfregulation and delay of gratification [46]. Cognitive neuroeconomics provides a model describing the roles of
emotion and cognition specifically in decision-making
under risk, and integrates external factors (eg, physical
environment, culture, group norms) and temporal focus (ie,
short-term vs long-term orientation) to explain the relationship between emotion, cognition, perceived risk, and
behavior [47••]. Managing conflicting emotions and affective cues will be critical to sustained sexual risk reduction
on PrEP, and these models may contribute to a better
understanding of the mechanisms through which PrEP
availability and/or adoption impacts risk perception and
behavior.
Finally, intervention development related to sustained
condom use on PrEP may be well informed by research on
the role of identity in predicting behavior, particularly
habitual health-related behavior. For example, repeated
behavior (eg, leafleting weekly for Greenpeace) may
represent or signify an identifiable role (eg, volunteer;
environmental activist), thereby becoming incorporated into
self-concept as both an exemplar and reinforcer of a
particular role-identity [48]. In many cases, role-identity
has an effect on behavior that is stronger than, and
independent of, an individual’s attitudes or perceived social
norms. In empirical investigations, the more salient or
central a particular role-identity is to an individual, the
more predictive it is of both behavioral intentions [49, 50]
and actual behavior [48]. Previous investigations in the
field of HIV prevention have focused almost exclusively on
the negative impact of role-identity on behavior, as evinced
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in the focus on the role of a “barebacker” identity in
predicting unprotected sex among men who have sex with
men. PrEP provides an opportunity to capitalize on the
positive impact of role-identity on behavior. Individuals
who adopt PrEP may be able to see this behavior as
reinforcing an identity as a “preventionist,” ie, “the type of
person who cares about reducing my risk of HIV infection.”
Construing PrEP as a reflection of a risk-reducing roleidentity might have a positive impact on sustained risk
reduction by replacing fatalistic attitudes associated with
prevention fatigue with a new emphasis on prevention
activism [4].

Conclusions
As we prepare for demonstrated efficacy of PrEP in
upcoming clinical trial results, empirical analogies across
research fields and scientific disciplines must be incorporated into the development of public education, behavioral
interventions, and systems of care for PrEP. Here, we have
outlined some of the most salient findings from behavioral
and social sciences relating to PrEP adoption, adherence,
and sustained risk reduction. Although this review is by no
means comprehensive, the examples it supplies are meant
to serve as a springboard for conceptualization of research
and practice around PrEP within an existing wealth of
relevant research. From the above review, we underscore
three specific research areas most relevant to PrEP
implementation.
First, communication to the general public and potential
PrEP adopters will require a clear, focused understanding of
the ways in which individuals process and apply probability
and relative risk information to their own health decisionmaking. Behavioral economics, decision sciences, and
health communication have much to teach us in developing
both social marketing campaigns and patient–provider
communication. Second, because of the uniquely nuanced
risk reduction message inherent in PrEP—ie, that it must
supplement traditional risk reduction efforts, rather than
replace them; that it might be only partially effective when
used alone—it is critical to understand the cognitive and
emotional processes related to the perception of personal
risk and its application to decision-making. Research
summarized here will be useful to the development of
support programs and risk reduction strategies for high-risk
individuals in the context of PrEP. Finally, PrEP represents
a unique opportunity to draw on empirical research
regarding the role of identity in shaping behavior. Many
behavioral interventions acknowledge the role of cognitive
and affective processes in shaping motivation and behavior,
but few have focused on the potential to shape risk
reduction by encouraging the development of an individu-
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al’s identity as “the type of person who protects myself
against HIV.”
Presenting PrEP use as part of the expression of a true
commitment to HIV prevention has the potential to promote
engagement in all three target behaviors. Individuals who
consider HIV prevention a critical part of their identity will
want to be PrEP adopters, but will also be conscientious
about adherence to PrEP and consistent condom use. This
potential for behavioral synergy is rare in the field, but is
important to consider in the development of PrEP-related
programs at all levels. As we prepare for the dissemination of
new biomedical approaches to HIV prevention, integrating
the state of the science across disciplines may result in
innovative strategies for implementation that can enhance
their success.
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